165 related articles for article (PubMed ID: 35538821)
1. pH-responsive Sulfated Hyaluronic Acid Nanoparticles Targeting Tumor Cells and CAFs for the Treatment of Breast Cancer.
Wang D; Wu J; Qi C; Dong J; Ding X; Yu G; Liu S; Zhang B; Gao Z; Wei X; Liu H
Recent Pat Anticancer Drug Discov; 2022; 18(2):200-210. PubMed ID: 35538821
[TBL] [Abstract][Full Text] [Related]
2. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted and multi-stimuli responsive drug delivery system for near-infrared light induced chemo-phototherapy and photoacoustic tomography.
Feng Q; Zhang Y; Zhang W; Shan X; Yuan Y; Zhang H; Hou L; Zhang Z
Acta Biomater; 2016 Jul; 38():129-42. PubMed ID: 27090593
[TBL] [Abstract][Full Text] [Related]
4. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
5. Enhancing the Inhibition of Breast Cancer Growth Through Synergistic Modulation of the Tumor Microenvironment Using Combined Nano-Delivery Systems.
Wu J; Lu Q; Zhao J; Wu W; Wang Z; Yu G; Tian G; Gao Z; Wang Q
Int J Nanomedicine; 2024; 19():5125-5138. PubMed ID: 38855730
[TBL] [Abstract][Full Text] [Related]
6. Rapid pH-responsive self-disintegrating nanoassemblies balance tumor accumulation and penetration for enhanced anti-breast cancer therapy.
Li J; Wang Y; Xu C; Yu Q; Wang X; Xie H; Tian L; Qiu Y; Guo R; Lu Z; Li M; He Q
Acta Biomater; 2021 Oct; 134():546-558. PubMed ID: 33882357
[TBL] [Abstract][Full Text] [Related]
7. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
9. Liver-Targeting and pH-Sensitive Sulfated Hyaluronic Acid Mixed Micelles for Hepatoma Therapy.
Li ZP; Tian GX; Jiang H; Pan RY; Lian B; Wang M; Gao ZQ; Zhang B; Wu JL
Int J Nanomedicine; 2019; 14():9437-9452. PubMed ID: 31819442
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-modified yeast β-glucan particles delivering doxorubicin for treatment of breast cancer.
He F; Xie C; Xu X
Carbohydr Polym; 2023 Aug; 314():120907. PubMed ID: 37173014
[TBL] [Abstract][Full Text] [Related]
11. Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment.
Zheng D; Wan C; Yang H; Xu L; Dong Q; Du C; Du J; Li F
Int J Nanomedicine; 2020; 15():10007-10028. PubMed ID: 33376321
[TBL] [Abstract][Full Text] [Related]
12. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
13. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment.
Zhang X; Zhao M; Cao N; Qin W; Zhao M; Wu J; Lin D
Biomater Sci; 2020 Mar; 8(7):1885-1896. PubMed ID: 32022813
[TBL] [Abstract][Full Text] [Related]
14. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
[TBL] [Abstract][Full Text] [Related]
15. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core-shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis.
Shi J; Ren Y; Ma J; Luo X; Li J; Wu Y; Gu H; Fu C; Cao Z; Zhang J
J Nanobiotechnology; 2021 Jun; 19(1):188. PubMed ID: 34162396
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment dual-responsive core-shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA.
Wang T; Yu X; Han L; Liu T; Liu Y; Zhang N
Int J Nanomedicine; 2017; 12():4773-4788. PubMed ID: 28740384
[TBL] [Abstract][Full Text] [Related]
17. Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies.
Jamshidi Z; Sadat Zavvar T; Ramezani M; Alibolandi M; Hadizadeh F; Abnous K; Taghdisi SM
Int J Pharm; 2022 Jul; 623():121892. PubMed ID: 35671850
[TBL] [Abstract][Full Text] [Related]
18. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
Haque ST; Islam RA; Gan SH; Chowdhury EH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
[No Abstract] [Full Text] [Related]
19. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
20. Enzyme/pH dual stimuli-responsive nanoplatform co-deliver disulfiram and doxorubicin for effective treatment of breast cancer lung metastasis.
Xiao P; Tao X; Wang H; Liu H; Feng Y; Zhu Y; Jiang Z; Yin T; Zhang Y; He H; Gou J; Tang X
Expert Opin Drug Deliv; 2023; 20(7):1015-1031. PubMed ID: 37452715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
